Ascendis Pharma A/S ADR (A1SN34)

Overview

Ascendis Pharma A/S is an innovative biopharmaceutical company that dedicates its efforts to addressing unmet medical needs through the development of groundbreaking therapies. Founded in 2006 and headquartered in Hellerup, Denmark, the company has established itself as a leader in the field of biopharmaceuticals, particularly focusing on rare diseases within endocrinology and oncology. Ascendis Pharma leverages its proprietary technology and deep scientific expertise to create therapies that aim to significantly improve patients' lives across the globe.

Products and Services

• SKYTROFA

  Ascendis Pharma's SKYTROFA is a pivotal drug designed for the treatment of growth hormone deficiency (GHD) in patients. This therapeutic solution represents the company's commitment to addressing the challenges faced by individuals dealing with GHD, offering them a potentially transformative treatment option.

• Endocrinology Rare Disease Product Candidates

  The company is developing a rich pipeline of three independent rare disease product candidates within the endocrinology domain. These are currently in clinical development stages, showcasing Ascendis Pharma's focused endeavor to bring novel treatments to patients suffering from rare endocrine disorders.

• Oncology Therapeutic Candidates

  In addition to its work in endocrinology, Ascendis Pharma is actively advancing therapeutic candidates in the field of oncology. This effort demonstrates the company's dedication to extending its impact beyond endocrinology and into other areas where there are substantial unmet medical needs, particularly in the treatment of various cancers.